Menu
Recruiting NCT06753838

Choice of Anticoagulant for Primary Hemostasis Studies With PFA200® (Platelet Function Analyser)

Observational Hemostasis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Sampling of 3 additional BAPA tubes.
Who it may be relevant to
Registry conditions: Hemostasis. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The PFA (platelet function analysis) test is prescribed for the exploration of primary hemostasis and the study of platelet-willebrand factor interaction. It is performed using citrated blood, with technical difficulties and frequent alarms that may be linked to the choice of anticoagulant (citrate). It is proposed to compare the results obtained with a conventional citrate tube and a BAPA tube, which is an anticoagulant used in clinical research and which blocks coagulation by another mechanism that would have less impact on blood platelets.

Interventions

  • Biological Sampling of 3 additional BAPA tubes
    the 3 additional tubes will be taken at the same time as the blood sample taken for the routine PFA test

Primary outcome measures

  • Occlusion time measurement [Time frame: at baseline]

Eligibility criteria

Inclusion criteria

  • Person having given their non-opposition
  • Person of legal age
  • Person receiving a haemostasis consultation at the haemophilia and haemorrhagic diseases treatment center followed by a blood sample with a PFA test prescribed by the doctor (the test is not added for the study).

Exclusion criteria

  • persons under legal protection (curatorship, guardianship)
  • persons subject to a court protection order
  • pregnant, parturient or breast-feeding women
  • adult incapable or unable to give consent
  • minor

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 1 center
  • CHU Dijon Bourgogne — Dijon

Identifiers

NCT: NCT06753838 · DE MAISTRE 2024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗